Fundraising FoxSparingVision
3 known investors
Find your way into SparingVision
Sign up to see every warm intro you have to SparingVision
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SparingVision team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system. The company's lead candidate, SPVN06, is being evaluated in the PRODYGY clinical trial.
Investors · 3
AdBio partnerslisted by AdBio partnersParis
How we know: AdBio partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Jeito Capitallisted by Jeito CapitalParis
How we know: Jeito Capital's portfolio page · Not right? Tell us
Ysios Capitallisted by Ysios CapitalBarcelona · $5.4M – $21.6M
How we know: Ysios Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Founder mafia
3 people who came through SparingVision went on to found or lead other companies.
Frequently asked questions
- What does SparingVision do?
- SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system. The company's lead candidate, SPVN06, is being evaluated in the PRODYGY clinical trial.
- Who are SparingVision's investors?
- SparingVision's investors include AdBio partners, Jeito Capital, Ysios Capital.